TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Sudarshan Pharma Ind Ltd
SUDARSHAN

Sudarshan Pharma Ind Ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 47/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 27 Oct 2026

₹34.66

Change

+2.67 (8.35%)

Open

₹33.82

Prev. Close

₹31.99

Day High

₹35.0

Day Low

₹32.1

Volume Analysis

Traded

87,439

Delivered

53,944

Delivery %

61.69%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •High debt-to-equity ratio (1.84)
  • •Below-average fundamentals quality score (47/100)

Opportunities (3)

  • •Strong 3-year EPS growth (49.6%)
  • •Strong 3-year revenue growth (15.1%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹38.64 ₹36.82 ₹35.74 ₹33.92 ₹32.84 ₹31.02 ₹29.94
Fibonacci ₹36.82 ₹35.71 ₹35.03 ₹33.92 ₹32.81 ₹32.13 ₹31.02
Camarilla ₹35.46 ₹35.19 ₹34.93 ₹33.92 ₹34.39 ₹34.13 ₹33.86

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

—

1 Month

—

3 Months

—

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹11.86

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

15.57%

Net margin 3.42% × asset turnover 1.1x × equity multiplier 4.14x

Company Overview

Sector

Chemicals

Market Cap

₹882 Cr

P/E (TTM)

35.1

ROE

16.3%

Book Value

₹6.44

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 28 Oct 2026. Not investment advice.

TopFund Analysis

Sudarshan Pharma Ind Ltd scores weakly on TopFund's composite fundamentals check within the Chemicals sector, at 47/100. The strongest factor is Growth (94/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: High debt-to-equity ratio (1.84); below-average fundamentals quality score (47/100). Strong 3-year EPS growth (49.6%).

TopFund Score — Fundamentals Quality

47/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Oct 2026 · How we calculate this →

Financial Strength

9

Growth

94

Valuation

28

Cash Flow

0

Corporate Governance

56

Momentum

67

Institutional Ownership

86

Business Quality

44

Liquidity

41

From Screener.in

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 54.2% CAGR over last 5 years
  • +Company's working capital requirements have reduced from 43.9 days to 17.1 days
  • −Stock is trading at 5.38 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Promoter holding has decreased over last quarter: -1.12%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Updates On Migration From SME Platform Of BSE To Capital Market Segment (Main Board) Of National Stock Exchange Of India Limited Of Sudarshan Pharma Industries Limited - Company Letter Bearing Ref. No. SPIL/CS/SE/2026-2027/20 Dated 21St May 2026 23 Oct

NSE approved listing of equity shares on main board from October 27, 2026.

Announcement under Regulation 30 (LODR)-Updates on Acquisition 07 Oct

Proposal to acquire 9.50% stake in Med Therapy Biotechnology Inc. terminated.

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 07 Oct

Submitted Regulation 74(5) certificates for quarter ended 30 September 2026.

Closure of Trading Window 30 Sep

Trading window closed from 1 October 2026 until 48 hours after Q2 FY2026-27 results.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 99 129 116 162 145 169 168 221 174
Expenses + 97 116 108 146 134 160 157 201 159
Operating Profit 2 13 8 16 11 9 11 20 16
OPM % 2.1% 10.15% 6.89% 9.86% 7.6% 5.45% 6.47% 9.14% 9.12%
Other Income + 1 -1 1 -1 1 2 2 4 1
Interest 4 4 4 4 6 6 6 8 8
Depreciation 1 1 1 1 1 1 1 1 1
Profit before tax -2 8 4 10 5 4 5 16 8
Tax % -21.94% 24.9% 24.94% 25.08% 26.8% 8.51% 20.19% 27.43% 25.33%
Net Profit + -1 6 3 7 4 4 4 11 6
EPS in Rs 0 0 0 0 0 0 0 0 0
Raw PDF — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 148 193 357 461 464 505 703 732
Expenses + 143 186 346 446 441 465 652 676
Operating Profit 5 7 11 15 23 40 51 56
OPM % 3.2% 3.7% 3.1% 3.2% 4.9% 8.0% 7.0% 8.0%
Other Income + 0 0 0 1 3 0 9 9
Interest 3 3 3 5 9 16 26 28
Depreciation 0 1 1 1 1 2 4 4
Profit before tax 2 4 7 9 15 22 31 33
Tax % 26.0% 25.0% 26.0% 26.0% 25.0% 26.0% 23.0% —
Net Profit + 1 3 5 7 11 16 23 25
EPS in Rs 0 0 0 0 0 1 1 1
Dividend Payout % 0.0% 0.0% 0.0% 10.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 10 13 20 77 88 107 131
Borrowings + 21 30 31 34 105 171 285
Other Liabilities + 18 47 77 97 67 100 202
Total Liabilities 58 99 138 232 283 402 642
Fixed Assets + 6 6 6 20 26 48 104
CWIP 0 0 1 0 2 23 3
Investments 0 0 0 12 14 30 0
Other Assets + 53 93 131 200 242 302 534
Total Assets 58 99 138 232 283 402 642
Equity Capital 10 10 10 24 24 24 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 1 3 -4 -29 6 -32 -2
Cash from Investing Activity + -3 -1 -1 -26 -5 -21 -78
Cash from Financing Activity + 0 -1 4 66 -12 53 79
Net Cash Flow -2 0 -1 11 -12 0 -1
Free Cash Flow -4 1 -5 -43 2 -54 -51
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 20 50 -19 -179 36 -74 7

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 57.39% → 57.81%
  Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 39.02% 41.2% 41.21% 29.54% 24.16% 23.07% 21.76% 22.79% 22.61% 21.65% 20.19%
Promoters 57.39% 57.39% 57.39% 57.39% 57.39% 57.39% 57.39% 57.39% 57.39% 58.93% 57.81%
Government 0.0% 0.0% 0.0% 0.0% 0.0% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05%
FII 3.58% 1.4% 1.4% 13.07% 18.45% 19.49% 20.79% 19.78% 19.95% 19.38% 21.94%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Chemicals — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sudarshan Pharma Ind Ltd (this stock) 882 35.1 5.39 16.3%
Advance Agrolife Limited 868 33.9 — 29.1%
Indo Amines Limited 918 11.3 2.33 19.7%
Sree Rayalseema Hhp Ltd. 815 8.27 0.84 10.5%
Dharmaj Crop Guard Ltd 804 13.4 1.8 13.3%
Amines & Plasticizers Ltd 804 20.8 2.75 13.2%
Zuari Agro Chemicals Ltd 784 2.53 0.37 1.24%

Which Mutual Funds Hold Sudarshan Pharma Ind Ltd?

Frequently Asked Questions about Sudarshan Pharma Ind Ltd

Community Sentiment

What are other investors saying about Sudarshan Pharma Ind Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.